{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106918","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.258296+00:00","generated_at":"2026-05-17T14:28:47.738018+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CalciMedica Q2 net loss $6.0M ($0.40/sh); cash $18.0M; KOURAGE trial data expected early 2026","bullets":["Net loss of $6.0M, or $0.40 per share, vs $4.0M ($0.36) in Q2 2024.","Cash and investments $18.0M; expected to fund operations into mid-2026.","R&D expenses $4.1M, G&A $2.6M; other income fell to $0.7M from $2.6M.","Enrollment ongoing in Phase 2 KOURAGE trial for AKI with respiratory failure; 150 patients planned.","Initial FDA meeting on Auxora for acute pancreatitis constructive; pivotal trial alignment expected end-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106918","json":"https://secwatch.observer/filing/0000950170-25-106918.json","markdown":"https://secwatch.observer/filing/0000950170-25-106918.md","text":"https://secwatch.observer/filing/0000950170-25-106918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000095017025106918/0000950170-25-106918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000095017025106918/ck0001534133-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:28:47.738018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}